CD24 and cancer: Moreover, the development of bispecific antibodies against CD24 and other targets like CD47 and VEGF receptors introduces an additive effect on phagocytosis-mediated cancer killing, indicating a potential for improved outcomes in treatments against malignancies like glioblastoma and hepatocellular carcinoma (148, 289).